ここがポイント!　抗菌薬耐性を攻略する抗菌薬の選び方・使い方

出版社： 文光堂
著者：
発行日： 2012-04-23
分野： 臨床医学：内科  >  感染症/AIDS
ISBN： 9784830610158
電子書籍版： 2012-04-23 （第1版第3刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

2,750 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

2,750 円(税込)

購入する

商品紹介

抗菌薬耐性菌のなかでも遭遇する頻度の高い病原微生物を取り上げ，使用される抗菌薬の基礎知識，抗微生物スペクトルの特徴，薬物耐性の問題，抗菌薬療法や感染制御のための知識などを解説した。

目次

  • ここがポイント！　抗菌薬耐性を攻略する抗菌薬の選び方・使い方

    ―目次―

    第1章　MRSA感染症（ディフィシル菌感染症を含む）
    　1　概　要
    　2　抗菌薬の基礎知識
    　3　抗微生物スペクトルの特徴
    　4　抗菌薬耐性の問題
    　5　抗菌薬療法のための知識
    　6　感染制御のための知識

    第2章　緑膿菌感染症
    　1　概　要
    　2　抗菌薬の基礎知識
    　3　抗微生物スペクトルの特徴
    　4　抗菌薬耐性の問題
    　5　抗菌薬療法のための知識
    　6　感染制御のための知識

    第3章　基質特異性拡張型β-ラクタマーゼ（ESBL）産生菌感染症
    　1　概　要
    　2　抗菌薬の基礎知識・抗微生物スペクトルの特徴
    　3　抗菌薬耐性の問題
    　4　抗菌薬療法のための知識
    　5　感染制御のための知識

    第4章　嫌気性菌が関与する感染症：誤嚥性肺炎
    　1　概　要
    　2　抗菌薬の基礎知識
    　3　抗微生物スペクトルの特徴
    　4　抗菌薬耐性の問題
    　5　抗菌薬療法のための知識
    　6　感染制御のための知識

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 MRSA感染症 ( ディフィシル菌感染症を含む )

P.53 掲載の参考文献
1) Reese RE, Betts RF : Antibiotic use. In Betts RF, Chapman SW, Penn RL, eds : A practical approach to infectious diseases, 5 th ed, Lippincott Williams & Wilkins, Philadelphia, 2003, p969-1153.
 
2) Gilbert DN, Moellering RC Jr, Eliopoulos GM, Chambers HF, Saag MS : 日本語版サンフォード感染症治療ガイド 2011, 第41版, ライフサイエンス出版, 東京, 2011.
 
3) MacGowan AP : Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother 51 (Suppl 2) : ii17-ii25, 2003.
PubMed
4) Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ : Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet 42 : 1411-1423, 2003.
 
5) Kosmidis C, Levine DP : Daptomycin : pharmacology and clinical use. Expert Opin Pharmacother 11 : 615-625, 2010.
PubMed
6) Edson RS, Terrell CL : The aminoglycosides. Mayo Clin Proc 74 : 519-528, 1999.
PubMed
7) Vesely JJ, Pien FD, Pien BC : Rifampin, a useful drug for nonmycobacterial infections. Pharmacotherapy 18 : 345-357, 1998.
PubMed
8) Cavalcanti AB, Goncalves AR, Almeida CS, Bugano DDG, Silva E : Teicoplanin versus vancomycin for proven or suspected infection (Review). Cochrane Database Syst Rev 6, 2010.
 
9) Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, Dalovisio JR, Levine DP : Vancomycin therapeutic guidelines : a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 49 : 325-327, 2009.
 
10) Sivagnanam S, Deleu D : Red man syndrome. Crit Care 7 : 119-120, 2003.
PubMed
11) Vinh DC, Rubinstein E : Linezolid : a review of safety and tolerability. J Infect 59 (S1) : S59-S74, 2009.
 
12) Miller BA, Gray A, LeBlanc TW, Sexton DJ, Martin AR, Slama TG : Acute eosinophilic pneumonia secondary to daptomycin : a report of three cases. Clin Infect Dis 50 : e63-e68, 2010.
PubMed
13) Xing G, Chen Z, Cao X : Mitochondrial rRNA and tRNA and hearing function. Cell Res 17 : 227-239, 2007.
PubMed
14) Healy DP, Sahai JV, Fuller SH, Polk RE : Vancomycin- induced histamine release and "red man syndrome" : comparison of 1- and 2-hour infusions. Antimicrob Agents Chemother 34 : 550-554, 1990.
PubMed
15) Rubinstein E, Isturiz R, Standiford HC, Smith LG, Oliphant TH, Cammarata S, Hafkin B, Le V, Remington J : Worldwide assessment of linezolid's clinical safety and tolerability : comparator- controlled phase III studies. Antimicrob Agents Chemother 47 : 1824-1831, 2003.
PubMed
16) Toh SM, Xiong L, Arias CA, Villegas MV, Lolans K, Quinn J, Mankin AS : Acquisition of a natural resistance gene renders a clinical strain of methicillin- resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol Microbiol 64 : 1506-1514, 2007.
 
17) Meka VG, Gold HS : Antimicrobial resistance to linezolid. Clin Infect Dis 39 : 1010-1015, 2004.
PubMed
18) Farrell DJ, Mendes RE, Ross JE, Jones RN : Linezolid surveillance program results for 2008 (LEADER Program for 2008). Diagn Microbiol Infect Dis 65 : 392-403, 2009.
PubMed
19) Sader HS, Jones RN : Antimicrobial susceptibility of Gram- positive bacteria isolated from US medical centers : results of the Daptomycin Surveillance Program (2007-2008). Diagn Microbiol Infect Dis 65 : 158-162, 2009.
PubMed
20) Sader HS, Moet GJ, Farrell DJ, Jones RN : Antimicrobial susceptibility of daptomycin and comparator agents tested against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci : trend analysis of a 6-year period in US medical centers (2005-2010). Diagn Microbiol Infect Dis 70 : 412-416, 2011.
PubMed
21) Boucher HW, Sakoulas G : Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis 45 : 601-608, 2007.
PubMed
22) Patel JB, Gorwitz RJ, Jernigan JA : Mupirocin resistance. Clin Infect Dis 49 : 935-941, 2009.
PubMed
23) Logman JF, Stephens J, Heeg B, Haider S, Cappelleri J, Nathwani D, Tice A, van Hout BA : Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections. Curr Med Res Opin 26 : 1565-1578, 2010.
PubMed
24) Shorr AF, Kunkel MJ, Kollef M : Linezolid versus vancomycin for Staphylococcus aureus bacteraemia : pooled analysis of randomized studies. J Antimicrob Chemother 56 : 923-929, 2005.
PubMed
25) Stryjewski ME, Szczech LA, Benjamin DK Jr, Inrig JK, Kanafani ZA, Engemann JJ, Chu VH, Joyce MJ, Reller LB, Corey GR, Fowler VG Jr : Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis 44 : 190-196, 2007.
PubMed
26) Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF ; Infectious Diseases Society of America : Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 52 : e18-e55, 2011.
 
27) Owens RC Jr, Lamp KC, Friedrich LV, Russo R : Postmarketing clinical experience in patients with skin and skin-structure infections treated with daptomycin. Am J Med 120 (Suppl 1) : S6-S12, 2007.
PubMed
28) Ardura MI, Mejias A, Katz KS, Revell P, McCracken GH Jr, Sanchez PJ : Daptomycin therapy for invasive Gram- positive bacterial infections in children. Pediatr Infect Dis J 26 : 1128-1132, 2007.
PubMed
29) Pelaez T, Alonso R, Perez C, Alcala L, Cuevas O, Bouza E : In vitro activity of linezolid against Clostridium difficile. Antimicrob Agents Chemother 46 : 1617-1618, 2002.
PubMed
30) Leffler DA, Lamont JT : Treatment of Clostridium difficile-associated disease. Gastroenterology 136 : 1899-1912, 2009.
PubMed
31) Stevens V, Dumyati G, Fine LS, Fisher SG, van Wijngaarden E : Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis 53 : 42-48, 2011.
PubMed
32) Bratzler DW, Houck PM : Surgical Infection Prevention Guideline Writers Workgroup : Antimicrobial prophylaxis for surgery : an advisory statement from the National Surgical Infection Prevention Project. Am J Surg 189 : 395-404, 2005.
PubMed
33) Ammerlaan HS, Kluytmans JA, Wertheim HF, Nouwen JL, Bonten MJ : Eradication of methicillin-resistant Staphylococcus aureus carriage : a systematic review. Clin Infect Dis 48 : 922-930, 2009.
PubMed
34) Wertheim HF, Verveer J, Boelens HA, van Belkum A, Verbrugh HA, Vos MC : Effect of mupirocin treatment on nasal, pharyngeal, and peritoneal carriage of Staphylococcus aureus in health adults. Antimicrob Agents Chemother 49 : 1465-1467, 2005.
 
35) Siegel JD, Rhinehart E, Jackson M, Chiarello L, the Healthcare Infection Control Practices Advisory Committee : Management of multidrug-resistant organisms in healthcare settings, 2006. Am J Infect Control 35 (Suppl 2) : S165-S193, 2007.
 
36) Sanchez Garcia M, De la Torre MA, Morales G, Pelaez B, Tolon MJ, Domingo S, Candel FJ, Andrade R, Arribi A, Garcia N, Martinez Sagasti F, Fereres J, Picazo J : Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 303 : 2260-2264, 2010.
 
37) Burns K, Morris-Downes M, Fawley WN, Smyth E, Wilcox MH, Fitzpatrick F : Infection due to C. difficile ribotype 078 : first report of cases in the Republic of Ireland. J Hosp Infect 75 : 287-291, 2010.
 

第2章 緑膿菌感染症

P.125 掲載の参考文献
1) Pier GB, Ramphal R : Pseudomonas aeruginosa. In Mandell GL, Bennett JE, Dolin R, eds : Mandell, Douglas, and Bennett's Principles and practice of infectious diseases, 7 th ed, Churchill Livingstone/Elsevier, Philadelphia, 2010, p2835-2860.
 
2) Paterson DL : The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 43 : S43-S48, 2006.
PubMed
3) Chambers HF : Penicillins and β-lactam inhibitors. In Mandell GL, Bennett JE, Dolin R, eds : Mandell, Douglas, and Bennett's Principles and practice of infectious diseases, 7 th ed, Churchill Livingstone/Elsevier, Philadelphia, 2010, p309-322.
 
4) Andes DR, Craig WA : Cephalosporins. In Mandell GL, Bennett JE, Dolin R, eds : Mandell, Douglas, and Bennett's Principles and practice of infectious diseases, 7 th ed, Churchill Livingstone/Elsevier, Philadelphia, 2010, p323-339.
 
5) Reese RE, Betts RF : Antibiotic use. In Betts RF, Chapman SW, Penn RL, eds : A practical approach to infectious diseases, 5 th ed, Lippincott Williams & Wilkins, Philadelphia, 2003, p969-1153.
 
6) Ambler RP : The structure of β-lactamases. Philos Trans R Soc Lond B Biol Sci 289 : 321-331, 1980.
 
7) Ambrose PG, Bhavnani SM, Owens RC Jr : Clinical pharmacodynamics of quinolones. Infect Dis Clin North Am 17 : 529-543, 2003.
PubMed
8) Kanellakopoulou K, Pagoulatou A, Stroumpoulis K, Vafiadou M, Kranidioti H, Giamarellou H, Giamarellos-Bourboulis EJ : Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans : implication for a bactericidal effect. J Antimicrob Chemother 61 : 1328-1331, 2008.
PubMed
9) Gilbert DN, Moellering RC Jr, Eliopoulos GM, Chambers HF, Saag MS : 日本語版サンフォード感染症治療ガイド 2011, 第41版, ライフサイエンス出版, 東京, 2011.
 
10) Edson RS, Terrell CL : The aminoglycosides. Mayo Clin Proc 74 : 519-528, 1999.
PubMed
11) Falagas ME, Kasiakou SK : Colistin : the revival of polymyxins for the management of multidrug-resistant gram- negative bacterial infections. Clin Infect Dis 40 : 1333-1341, 2005.
PubMed
12) Levin AS, Barone AA, Penco J, Santos MV, Marinho IS, Arruda EA, Manrique EI, Costa SF : Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 28 : 1008-1011, 1999.
PubMed
13) Kallel H, Bahloul M, Hergafi L, Akrout M, Ketata W, Chelly H, Hamida CB, Rekik N, Hammami A, Bouaziz M : Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU. Int J Antimicrob Agents 28 : 366-369, 2006.
PubMed
14) Giamarellou H, Kanellakopoulou K : Current therapies for Pseudomonas aeruginosa. Crit Care Clin 24 : 261-278, 2008.
PubMed
15) Slama TG : Clinical review : balancing the therapeutic, safety, and economic issues underlying effective antipseudomonal carbapenem use. Crit Care 12 : 233, 2008.
PubMed
16) 齋藤厚, 砂川慶介, 中島光好, 炭山嘉伸, 池澤善郎, 比嘉太, 佐々木緊, 矢野裕二 : 抗菌薬投与に関連するアナフィラキシー対策のガイドライン (2004年版), 社団法人日本化学療法学会臨床試験委員会皮内反応検討特別部会, 2004.
 
17) van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HM, Rowlands S, Stricker BH : Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids. Arch Intern Med 163 : 1801-1807, 2003.
PubMed
18) Leveque D, Jehl F : Molecular determinants of fluoroquinolone antibacterial agents pharmacokinetics. Curr Clin Pharmacol 4 : 191-197, 2009.
PubMed
19) Craig WA : Optimizing aminoglycoside use. Crit Care Clin 27 : 107-121, 2011.
PubMed
20) Strateva T, Yordanov D : Pseudomonas aeruginosa-a phenomenon of bacterial resistance. J Med Microbiol 58 : 1133-1148, 2009.
PubMed
21) Zavascki AP, Carvalhaes CG, Picao RC, Gales AC : Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii : resistance mechanisms and implications for therapy. Expert Rev Anti Infect Ther 8 : 71-93, 2010.
PubMed
22) Lister PD, Wolter DJ, Hanson ND : Antibacterial-resistant Pseudomonas aeruginosa : clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 22 : 582-610, 2009.
PubMed
23) Hirsch EB, Tam VH : Impact of multidrug- resistant Pseudomonas aeruginosa infection on patient outcomes. Expert Rev Pharmacoecon Outcomes Res 10 : 441-451, 2010.
PubMed
24) Wispelwey B : Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolones. Clin Infect Dis 41 (Suppl 2) : S127-S135, 2005.
PubMed
25) Giske CG, Monnet DL, Cars O, Carmeli Y ; ReAct- Action on Antibiotic Resistance : Clinical and economic impact of common multidrug- resistant gram- negative bacilli. Antimicrob Agents Chemother 52 : 813-821, 2008.
PubMed
26) Peterson LR : Squeezing the antibiotic balloon : the impact of antimicrobial classes on emerging resistance. Clin Microbiol Infect 11 (Suppl 5) : 4-16, 2005.
 
27) Hooper DC, Strahilevitz J : Quinolones. In Mandell GL, Bennett JE, Dolin R, eds : Mandell, Douglas, and Bennett's Principles and practice of infectious diseases, 7 th ed, Churchill Livingstone/Elsevier, Philadelphia, 2010, p487-510.
 
28) Paul M, Leibovici L : Combination antimicrobial treatment versus monotherapy : the contribution of meta-analyses. Infect Dis Clin North Am 23 : 277-293, 2009.
PubMed
29) Manchanda V, Sanchaita S, Singh NP : Multidrug resistant Acinetobacter. J Glob Infect Dis 2 : 291-304, 2010.
PubMed
30) Murphy TF : Pseudomonas aeruginosa in adults with chronic obstructive pulmonary diseases. Curr Opin Pulm Med 15 : 138-142, 2009.
PubMed
31) Safdar N, Handelsman J, Maki DG : Dose combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 4 : 519-527, 2004.
 
32) Bassetti M, Righi E, Viscoli C : Pseudomonas aeruginosa serious infections : mono or combination antimicrobial therapy? Curr Med Chem 15 : 517-522, 2008.
PubMed
33) Jacoby GA : AmpC β-lactamases. Clin Microbiol Rev 22 : 161-182, 2009.
 
34) Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, Noreddin AM, Karlowsky JA : Comparative review of the carbapenems. Drugs 67 : 1027-1052, 2007.
PubMed
35) Petrosillo N, Ioannidou E, Falagas ME : Colistin monotherapy vs. combination therapy : evidence from microbiological, animal and clinical studies. Clin Microbiol Infect 14 : 816-827, 2008.
PubMed
36) Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, Raad II, Rijnders BJ, Sherertz RJ, Warren DK : Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection : 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 49 : 1-45, 2009.
 
37) American Thoracic Society ; Infectious Diseases Society of America : Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 15 : 388-416, 2005.
 
38) Torres A, Ferrer M, Badia JR : Treatment guidelines and outcomes of hospital-acquired and ventilator-associated pneumonia. Clin Infect Dis 51 (Suppl 1) : S48-S53, 2010.
 
39) Hooton TM, Bradley SF, Cardenas DD, Colgan R, Geerlings SE, Rice JC, Saint S, Schaeffer AJ, Tambayh PA, Tenke P, Nicolle LE ; Infectious Diseases Society of America : Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults : 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis 50 : 625-663, 2010.
 
40) Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM, Whitley RJ : Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 39 : 1267-1284, 2004.
PubMed
41) Fung HB, Chang JY, Kuczynski S : A practical guide to the treatment of complicated skin and soft tissue infections. Drugs 63 : 1459-1480, 2003.
 
42) Falagas ME, Kopterides P : Risk factors for the isolation of multi- drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa : a systematic review of the literature. J Hosp Infect 64 : 7-15, 2006.
PubMed
43) Bratu S, Quale J, Cebular S, Heddurshetti R, Landman D : Multidrug-resistant Pseudomonas aeruginosa in Brooklyn, New York : molecular epidemiology and in vitro activity of polymyxin B. Eur J Clin Microbiol Infect Dis 24 : 196-201, 2005.
PubMed
44) Jones RN : Microbial etiologies of hospital- acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis 51 (Suppl 1) : S81-S87, 2010.
PubMed
45) Craven DE : What is healthcare-associated pneumonia, and how should it be treated? Curr Opin Infect Dis 19 : 153-160, 2006.
 
46) Grammatikos AP, Siempos II, Michalopoulos A, Falagas ME : Optimal duration of the antimicrobial treatment of ventilator-acquired pneumonia. Expert Rev Anti Infect Ther 6 : 861-866, 2008.
PubMed
47) Zilberberg MD, Chen J, Mody SH, Ramsey AM, Shorr AF : Imipenem resistance of Pseudomonas in pneumonia : a systematic literature review. BMC Pulm Med 10 : 45, 2010.
PubMed
48) Siegel JD, Rhinehart E, Jackson M, Chiarello L ; Healthcare Infection Control Practices Advisory Committee : Management of multidrug-resistant organisms in healthcare settings, 2006. Am J Infect Control 35 (Suppl 2) : S165-S193, 2007.
 
49) Stolz D, Smyrnios N, Eggimann P, Pargger H, Thakkar N, Siegemund M, Marsch S, Azzola A, Rakic J, Mueller B, Tamm M : Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia : a randomised study. Eur Respir J 34 : 1364-1375, 2009.
PubMed
50) 国公立大学附属病院感染対策協議会 : 人工呼吸器関連肺炎防止. 国公立大学附属病院感染対策協議会 病院感染対策ガイドライン, 改訂第3版, 2011.
 
51) Gould CV, Umscheid CA, Agarwal RK, Kuntz G, Pegues DA ; Healthcare Infection Control Practices Advisory Committee : Guideline for prevention of catheter-associated urinry tract infections 2009. Infect Control Hosp Epidemiol 31 : 319-326, 2010.
 
52) Pakyz AL, Oinonen M, Polk RE : Relationship of carbapenem restriction in 22 university teaching hospitals to carbapenem use and carbapenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 53 : 1983-1986, 2009.
PubMed
53) Kaki R, Elligsen M, Walker S, Simor A, Palmay L, Daneman N : Impact of antimicrobial stewardship in critical care : a systematic review. J Antimicrob Chemother 66 : 1223-1230, 2011.
PubMed
54) Niederman MS : De-escalation therapy in ventilator-associated pneumonia. Curr Opin Crit Care 12 : 452-457, 2006.
PubMed
55) McGeer A : News in antimicrobial resistance : documenting the progress of pathogens. Infect Control Hosp Epidemiol 25 : 97-98, 2004.
PubMed
56) Kohlenberg A, Weitzel-Kage D, van der Linden P, Sohr D, Vogeler S, Kola A, Halle E, Ruden H, Weist K : Outbreak of carbapenem-resistant Pseudomonas aeruginosa infection in a surgical intensive care unit. J Hosp Infect 74 : 350-357, 2010.
 
57) Gillespie JL, Arnold KE, Noble-Wang J, Jensen B, Arduino M, Hageman J, Srinivasan A : Outbreak of Pseudomonas aeruginosa infections after transrectal ultrasound-guided prostate biopsy. Urology 69 : 912-914, 2007.
PubMed

第3章 基質特異性拡張型β - ラクタマーゼ ( ESBL ) 産生菌感染症

P.156 掲載の参考文献
1) Falagas ME, Karageorgopoulos DE : Extended-spectrum β-lactamase-producing organisms. J Hosp Infect 73 : 345-354, 2009.
 
2) Pfaller MA, Segreti J : Overview of the epidemiological profile and laboratory detection of extended-spectrum β-lactamases. Clin Infect Dis 42 : S153-S163, 2006.
 
3) Rodriguez-Bano J, Pascual A : Clinical significance of extended-spectrum β-lactamases. Expert Rev Anti Infect Ther 6 : 671-683, 2008.
 
4) Rawat D, Nair D : Extended-spectrum β- lactamases in Gram Negative Bacteria. J Glob Infect Dis 2 : 263-274, 2010.
 
5) Yang K, Guglielmo BJ : Diagnosis and treatment of extended-spectrum and AmpC β-lactamase-producing organisms. Ann Pharmacother 41 : 1427-1435, 2007.
 
6) Ambler RP : The structure of β-lactamases. Philos Trans R Soc Lond B Biol Sci 289 : 321-331, 1980.
 
7) メロペン特定使用成績調査 (全国感受性) 研究会 : Meropenemを含む各種注射用抗菌薬に対する2009年臨床分離株の感受性サーベイランス. Jpn J Antibiotics 64 : 53-95, 2011.
 
8) Luvsansharav UO, Hirai I, Niki M, Nakata A, Yoshinaga A, Moriyama T, Yamamoto Y : Prevalence of fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae among healthy adult people in Japan. J Infect Chemother 17 : 722-725, 2011.
 
9) Monet GJ, Jones RN, Biedenbach DJ, Stilwell MG, Fritsche TR : Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe : report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagn Microbiol Infect Dis 57 : 7-13, 2007.
 
10) Hoban DJ, Nicolle LE, Hawser S, Bouchillon S, Badal R : Antimicrobial susceptibility of global inpatient urinary tract isolates of Escherichia coli : results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program : 2009-2010. Diagn Microbiol Infect Dis 70 : 507-511, 2011.
 
11) Oteo J, Perez-Vazquez M, Campos J : Extended-spectrum β-lactamase producing Escherichia coli : changing epidemiology and clinical impact. Curr Opin Infect Dis 23 : 320-326, 2010.
 
12) Pitout JD : Multiresistant Enterobacteriaceae : new threat of an old problem. Expert Rev Anti Infect Ther 6 : 657-669, 2008.
PubMed
13) Pitout JD : Infections with extended-spectrum β-lactamase-producing enterobacteriaceae : changing epidemiology and drug treatment choices. Drugs 70 : 313 -333, 2010.
 
14) Ramphal R, Ambrose PG : Extended-spectrum β-lactamases and clinical outcomes : current data. Clin Infect Dis 42 : S164-S172, 2006.
 
15) Pitout JD, Laupland KB : Extended-spectrum β-lactamase-producing Enterobacteriaceae : an emerging public-health concern. Lancet Infect Dis 8 : 159-166, 2008.
 
16) Pena C, Gudiol C, Calatayud L, Tubau F, Dominguez MA, Pujol M, Ariza J, Gudiol F : Infections due to Escherichia coli producing extended-spectrum β-lactamase among hospitalised patients : factors influencing mortality. J Hosp Infect 68 : 116-122, 2008
 
17) Craven DE, Chroneou A : Nosocomial pneumonia. In Mandell GL, Bennett JE, Dolin R, eds : Mandell, Douglas, and Bennett's Principles and practice of infectious diseases, 7 th ed, Churchill Livingstone/Elsevier, Philadelphia, 2010, p3717-3724.
 
18) Gilbert DN, Moellering RC Jr, Eliopoulos GM, Chambers HF, Saag MS : 日本語版サンフォード感染症治療ガイド 2011, 第41版, ライフサイエンス出版, 東京, 2011.
 
19) Hsueh PR, Hoban DJ, Carmeli Y, Chen SY, Desikan S, Alejandria M, Ko WC, Binh TQ : Consensus review of the epidemiology and appropriate antimicrobial therapy of complicated urinary tract infections in Asia-Pacific region. J Infect 63 : 114-123, 2011.
 
20) Clinical and Laboratory Standards Institute (CLSI) : Performance standards for antimicrobial susceptibility testing ; Twenty- first informational supplement, CLSI, Wayne, Pennsylvania, 2010.
 
21) Ben-Ami R, Schwaber MJ, Navon-Venezia S, Schwartz D, Giladi M, Chmelnitsky I, Leavitt A, Carmeli Y : Influx of extended-spectrum β-lactamase-producing enterobacteriaceae into the hospital. Clin Infect Dis 42 : 925-934, 2006.
 
22) 畠山薫, 奥野ルミ, 遠藤美代子, 柳川義勢 : 集団下痢症事例由来ヒト糞便からのバンコマイシン耐性腸球菌および基質特異性拡張型βラクタマーゼ産生菌の検出の試み. 東京健安研セ年報 57 : 69-72, 2006.
 
23) 仁木真里恵, 平井到, 山本容正 : 医療系学生における基質特異性拡張型βラクタマーゼ産生腸内細菌保持率. 環境感染誌 26 : 154-156, 2011.
 
24) Alsterlund R, Axelsson C, Olsson-Liljequist B : Long- term carriage of extended-spectrum beta-lactamase-producing Escherichia coli. Scand J Infect Dis 44 : 51-54, 2011.
PubMed
25) Mesa RJ, Blanc V, Blanch AR, Cortes P, Gonzalez JJ, Lavilla S, Miro E, Muniesa M, Saco M, Tortola MT, Mirelis B, Coll P, Llagostera M, Prats G, Navarro F : Extended-spectrum β-lactamase-producing Enterobacteriaceae in different environments (humans, food, animal farms and sewage). J Antimicrob Chemother 58 : 211-215, 2006.
 
26) Valverde A, Grill F, Coque TM, Pintado V, Baquero F, Canton R, Cobo J : High rate of intestinal colonization with extended-spectrum -β-lactamase-producing organisms in household contacts of infected community patients. J Clin Microbiol 46 : 2796-2799, 2008.
 
27) Conterno LO, Shymanski J, Ramotar K, Toye B, Zvonar R, Roth V : Impact and cost of infection control measures to reduce nosocomial transmission of extended-spectrum β-lactamase-producing organisms in a non-outbreak setting. J Hosp Infect 65 : 354-360, 2007.
 
28) Laurent C, Rodriguez-Villalobos H, Rost F, Strale H, Vincent JL, Deplano A, Struelens MJ, Byl B : Intensive care unit outbreak of extended-spectrum β-lactamase-producing Klebsiella pneumoniae controlled by cohorting patients and reinforcing infection control measures. Infect Control Hosp Epidemiol 29 : 517-524, 2008.
 
29) Manzur A, Tubau F, Pujol M, Calatayud L, Dominguez MA, Pena C, Sora M, Gudiol F, Ariza J : Nosocomial outbreak due to extended-spectrum-beta-lactamase- producing Enterobacter cloacae in a cardiothoracic intensive care unit. J Clin Microbiol 45 : 2365-2369, 2007.
 
30) Calbo E, Freixas N, Xercavins M, Riera M, Nicolas C, Monistrol O, Sole Mdel M, Sala MR, Vila J, Garau J : Foodborne nosocomial outbreak of SHV1 and CTX-M-15-producing Klebsiella pneumoniae : epidemiology and control. Clin Infect Dis 52 : 743-749, 2011.
PubMed
31) Aumeran C, Poincloux L, Souweine B, Robin F, Laurichesse H, Baud O, Bommelaer G, Traore O : Multidrug-resistant Klebsiella pneumoniae outbreak after endoscopic retrograde cholangiopancreatography. Endoscopy 42 : 895-899, 2010.
PubMed
32) Lavilla S, Gonzalez- Lopez JJ, Miro E, Dominguez A, Llagostera M, Bartolome RM, Mirelis B, Navarro F, Prats G : Dissemination of extended-spectrum β-lactamase-producing bacteria : the food-borne outbreak lesson. J Antimicrob Chemother 61 : 1244-1251, 2008.
 
33) Kaier K, Frank U, Conrad A, Meyer E : Seasonal and ascending trends in the incidence of carriage of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella species in 2 German hospitals. Infect Control Hosp Epidemiol 31 : 1154-1159, 2010.
 
34) Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, Mulazimoglu L, Trenholme G, Klugman KP, Bonomo RA, Rice LB, Wagener MM, McCormack JG, Yu VL : International prospective study of Klebsiella pneumoniae bacteremia : implications of extended-spectrum β-lactamase production in nosocomial Infections. Ann Intern Med 140 : 26-32, 2004.
 
35) Hyle EP, Lipworth AD, Zaoutis TE, Nachamkin I, Bilker WB, Lautenbach E : Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum β-lactamase-producing enterobacteriaceae : variability by site of infection. Arch Intern Med 165 : 1375-1380, 2005.
 
36) Conte MP, Venditti M, Chiarini F, D'Ettorre G, Zamboni I, Scoarughi GL, Gallinelli C, Orsi GB : Extended spectrum beta-lactamase-producing Klebsiella pneumoniae outbreaks during a third generation cephalosporin restriction policy. J Chemother 17 : 66-73, 2005.
 
37) Randrianirina F, Vedy S, Rakotovao D, Ramarokoto CE, Ratsitohaina H, Carod JF, Ratsima E, Morillon M, Talarmin A : Role of contaminated aspiration tubes in nosocomial outbreak of Klebsiella pneumoniae producing SHV-2 and CTX-M-15 extended-spectrum β-lactamases. J Hosp Infect 72 : 23-29, 2009.
 

第4章 嫌気性菌が関与する感染症 : 誤嚥性肺炎

P.190 掲載の参考文献
1) 厚生労働省 : 平成22年人口動態統計月報年計 (概数) の概況. http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/geppo/nengai10/toukei07.html
 
2) 嚥下性肺疾患研究会 : 嚥下性肺疾患の診断と治療. ファイザー, 東京, 2003.
 
3) 日本呼吸器学会 : 医療・介護関連肺炎 (NHCAP) 診療ガイドライン, 2011.
 
4) Girard D, Finegan SM, Dunnem W, Lamem E : Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models. J Antimicrob Chemother 56 : 365-371, 2005.
 
5) Tessier PR, Kimm K, Zhou W, Xuan D, Li C, Ye M, Nightingale CH, Nicolau DP : Pharmacodynamic assessment of clarithromycin in a murine model of pneumococcal pneumonia. Antimicrob Agents Chemother 46 : 1425 -1434, 2002.
 
6) Zhanel GG, Dueck M, Hoban DJ, Vercaigne LM, Embil JM, Gin AS, Karlowsky JA : Review of macrolides and ketolides : focus on respiratory tract infections. Drugs 16 : 443-498, 2001.
PubMed
7) Reese RE, Betts RF : Antibiotic use. In Betts RF, Chapman SW, Penn RL, eds : A Practical approach to infectious diseases, 5 th ed, Lippincott Williams & Wilkins, Philadelphia, 2003, p969-1153.
 
8) Sivapalasingam S, Steigbigel NH : Macrolides, clindamycin, and ketolides. In Mandell GL, Bennett JE, Dolin R, eds : Mandell, Douglas, and Bennett's Principles and practice of infectious diseases, 7 th ed, Churchill Livingstone/Elsevier, Philadelphia, 2010, p427-448.
 
9) Gilbert DN, Moellering RC Jr, Eliopoulos GM, Chambers HF, Saag MS : 日本語版サンフォード感染症治療ガイド 2011, 第41版, ライフサイエンス出版, 東京, 2011.
 
10) 霧島正浩 : 各都道府県から分離された新鮮臨床分離株86万株の各種抗菌薬に対する感受性検査成績 (第7報 : 2008年4月～2009年3月). 診療と新薬 46 : 975-1031, 2009.
 
11) Takayanagi N, Kagiyama N, Ishiguro T, Tokunaga D, Sugita Y : Etiology and outcome of community-acquired lung abscess. Respiration 80 : 98-105, 2010.
PubMed
12) El-Solh AA, Pietrantoni C, Bhat A, Aquilina AT, Okada M, Grover V, Gifford N : Microbiology of severe aspiration pneumonia in institutionalized elderly. Am J Respir Crit Care Med 167 : 1650-1654, 2003.
PubMed
13) Bartlett JG, O'Keefe P, Tally FP, Louie TJ, Gorbach SL : Bacteriology of hospital-acquired pneumonia. Arch Intern Med 146 : 868-871, 1986.
 
14) Depardieu F, Podglajen I, Leclercq R, Collatz E, Courvalin P : Modes and modulations of antibiotic resistance gene expression. Clin Microbiol Rev 20 : 79-114, 2007.
PubMed
15) Reza Shariatzadeh M, Huang JQ, Marrie TJ : Differences in the features of aspiration pneumonia according to site of acquisition : community or continuing care facility. J Am Geriatr Soc 54 : 296-302, 2006.
PubMed
16) Cabre M, Serra-Prat M, Palomera E, Almirall J, Pallares R, Clave P : Prevalence and prognostic implications of dysphagia in elderly patients with pneumonia. Age Ageing 39 : 39-45, 2010.
PubMed
17) Chiba H, Ohrui T, Matsui T, Fukushima T, Sasaki H : Benefits of pneumococcal vaccination for bedridden patients. J Am Geriatr Soc 52 : 1410, 2010.
 
18) Christenson B, Lundbergh P, Hedlund J, Ortqvist A : Effects of a large- scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older : a prospective study. Lancet 357 : 1008-1011, 2001.
 
19) Logemann JA, Gensler G, Robbins J, Lindblad AS, Brandt D, Hind JA, Kosek S, Dikeman K, Kazandjian M, Gramigna GD, Lundy D, McGarvey-Toler S, Miller Gardner PJ : A randomized study of three interventions for aspiration of thin liquids in patients with dementia or Parkinson's disease. J Speech Lang Hear Res 51 : 173-183, 2008.
PubMed
20) Robbins J, Gensler G, Hind J, Logemann JA, Lindblad AS, Brandt D, Baum H, Lilienfeld D, Kosek S, Lundy D, Dikeman K, Kazandjian M, Gramigna GD, McGarvey-Toler S, Miller Gardner PJ : Comparison of 2 interventions for liquid aspiration on pneumonia incidence : a randomized trial. Ann Intern Med 148 : 509-518, 2008.
PubMed
21) Bonhoeffer J, Trachsel D, Hammer J, Nava E, Heininger U : Lemierre syndrome and nosocomial transmission of Fusobacterium necrophorum from patient to physician. Klin Padiatr 222 : 464-466, 2010.
PubMed

書評

最近チェックした商品履歴

Loading...